WallStSmart

Abbott Laboratories (ABT)vsCVRx Inc (CVRX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 76305% more annual revenue ($45.13B vs $59.07M). ABT leads profitability with a 13.9% profit margin vs -89.1%. ABT earns a higher WallStSmart Score of 56/100 (C).

ABT

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 6.0Value: 4.7Quality: 6.0
Piotroski: 4/9Altman Z: 2.71

CVRX

Avoid

29

out of 100

Grade: F

Growth: 7.3Profit: 2.0Value: 6.7Quality: 4.5
Piotroski: 3/9Altman Z: -7.47
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTSignificantly Overvalued (-28.5%)

Margin of Safety

-28.5%

Fair Value

$70.89

Current Price

$91.07

$20.18 premium

UndervaluedFair: $70.89Overvalued
CVRXUndervalued (+71.4%)

Margin of Safety

+71.4%

Fair Value

$21.26

Current Price

$5.38

$15.88 discount

UndervaluedFair: $21.26Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT1 strengths · Avg: 9.0/10
Market CapQuality
$151.49B9/10

Large-cap with strong market position

CVRX1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
19.6%8/10

19.6% revenue growth

Areas to Watch

ABT1 concerns · Avg: 2.0/10
EPS GrowthGrowth
-19.7%2/10

Earnings declined 19.7%

CVRX4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$156.03M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-180.9%2/10

ROE of -180.9% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap. PEG of 1.30 suggests the stock is reasonably priced for its growth.

Bull Case : CVRX

The strongest argument for CVRX centers on Revenue Growth. Revenue growth of 19.6% demonstrates continued momentum.

Bear Case : ABT

The primary concerns for ABT are EPS Growth.

Bear Case : CVRX

The primary concerns for CVRX are EPS Growth, Market Cap, Piotroski F-Score. Debt-to-equity of 2.03 is elevated, increasing financial risk.

Key Dynamics to Monitor

ABT profiles as a value stock while CVRX is a growth play — different risk/reward profiles.

CVRX carries more volatility with a beta of 0.77 — expect wider price swings.

CVRX is growing revenue faster at 19.6% — sustainability is the question.

ABT generates stronger free cash flow (916M), providing more financial flexibility.

Bottom Line

ABT scores higher overall (56/100 vs 29/100). CVRX offers better value entry with a 71.4% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

CVRx Inc

HEALTHCARE · MEDICAL DEVICES · USA

CVRx, Inc. develops implantable technology for the treatment of patients with high blood pressure / hypertension and heart failure.

Want to dig deeper into these stocks?